Muller H K, Halliday G M, Knight B A
Br J Cancer. 1985 Jul;52(1):81-5. doi: 10.1038/bjc.1985.152.
The chemical carcinogen 7,12-dimethylbenz (a) anthracene (DMBA) is a potent carcinogen which, when applied to the skin of BALB/c mice weekly for 7-8 weeks, causes the induction of macroscopically visible skin tumours. We report that DMBA also depletes Langerhans cells (LC) from treated skin; the number of cutaneous LC is reduced by nearly 50% 3 days after the first application of DMBA, and continues to decrease upon further treatment. After 7-8 weeks of DMBA application, while tumours are becoming macroscopically visible, there is a considerably lower LC density in treated skin. Upon cessation of the DMBA treatment, the LC repopulate the skin, returning to control values within 55-64 days. During this repopulation of the skin by LC, the tumours begin to decrease in size. Since LC function as local cutaneous antigen-presenting cells, and are responsible for initiation of an immune response against antigens in the skin, their depletion during tumour induction may allow DMBA-transformed cells to circumvent the immune system and form tumours. Their reappearance associated with tumour regression suggests that the LC are involved in an immune response against the tumours.
化学致癌物7,12 - 二甲基苯并(a)蒽(DMBA)是一种强效致癌物,当每周应用于BALB/c小鼠皮肤7 - 8周时,会诱发肉眼可见的皮肤肿瘤。我们报告称,DMBA还会使处理过的皮肤中的朗格汉斯细胞(LC)减少;首次应用DMBA 3天后,皮肤LC数量减少近50%,并在进一步处理后持续下降。应用DMBA 7 - 8周后,当肿瘤肉眼可见时,处理过的皮肤中LC密度显著降低。停止DMBA处理后,LC重新在皮肤中聚集,在55 - 64天内恢复到对照值。在LC重新聚集到皮肤的过程中,肿瘤开始缩小。由于LC作为局部皮肤抗原呈递细胞,负责启动针对皮肤中抗原的免疫反应,它们在肿瘤诱导过程中的减少可能使DMBA转化的细胞规避免疫系统并形成肿瘤。它们与肿瘤消退相关的再次出现表明LC参与了针对肿瘤的免疫反应。